The present disclosure is directed to fatty-acid glycerol ester derivative compounds containing a targeting bisphosphonate group. The disclosure further include pharmaceutical or biomedical compositions comprising these compounds, and methods of using these compounds and compositions forming microbubbles. The microbubbles have affinity for metal-containing, especially calcium-containing, bodies and/or biological targets. In certain embodiments, these compositions are useful for providing targeted placement of microbubbles capable of cavitation on application of high frequency energy

A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed laser beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature up to eleven degrees Celsius to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.

A process for preventing or treating myopia includes applying a pulsed energy, such as a pulsed light beam, to tissue of an eye having myopia or a risk of having myopia. The source of pulsed energy has energy parameters including wavelength or frequency, duty cycle and pulse train duration, which are selected so as to raise an eye tissue temperature to achieve therapeutic or prophylactic effect, such as stimulating heat shock protein activation in the eye tissue. The average temperature rise of the eye tissue over several minutes is maintained at or below a predetermined level so as not to permanently damage the eye tissue.

A method and/or system are provided for improving kidney function and/or increasing Glomerular Filtration Rate (GFR) of the renal system, by applying acoustic and/or ultrasonic energy to one or more of the kidneys. The method suggests either focused or non-focused (or combined) energy delivery, optionally in a noninvasive approach, which could also be implemented invasively and/or by implantable device.

Potential applications of this technique, include, but are not restricted to, treatment of renal disorders such as CKD (Chronic Kidney Disease) and/or AKI (Acute Kidney Injury), short term or long term intervention in kidney function for therapeutic or diagnostic purposes, modifying urine output in heart failure, modulating blood volume and/or pressure, and modulating clearance of compounds in the blood are typically difficult to extract from the kidneys, such as iodine, other imaging contrast media, and similar compounds.

Human and animal biofilms and pathogens are treated with extracorporeal acoustic pressure shock waves at a location of prosthesis or implant in a body.

Various approaches for computationally generating a protocol for treatment of one or more target BBB regions within a tissue region of interest using a source of focused ultrasound include specifying (i) settings of sonication parameters for applying one or more sequence of sonications to the target BBB region using the source of focused ultrasound and (ii) a characteristic of microbubbles selected to be administered into the target BBB region; electronically simulating treatment in accordance with the protocol at least in part by computationally executing the sequence(s) of sonications and computationally administering the microbubbles having the characteristic; and computationally predicting a tissue disruption effect of the target BBB region resulting from the treatment.

A processor-controlled, energy-based therapy apparatus includes a device configured to provide therapeutic energy to a patient and a processor that controls the output of the device. The output of the device is based on output profiles programmed into the processor. The output profiles include a therapeutic energy output profile and a ramp-up energy profile. The therapeutic energy output profile includes a desired target energy level and a therapeutic duration for controlling the output of the device during a therapeutic period. The ramp-up energy output profile includes an initial treatment energy level and a ramp-up duration for controlling the output of the device during a ramp-up period. The energy output specified by the ramp-up energy output profile incrementally increases over the ramp-up duration as a function of the desired target energy level and the ramp-up duration.

The present disclosure is directed to fatty-acid glycerol ester derivative compounds containing a targeting bisphosphonate group. The disclosure further include pharmaceutical or biomedical compositions comprising these compounds, and methods of using these compounds and compositions forming microbubbles. The microbubbles have affinity for metal-containing, especially calcium-containing, bodies and/or biological targets. In certain embodiments, these compositions are useful for providing targeted placement of microbubbles capable of cavitation on application of high frequency energy.

Disclosed herein is a non-invasive treatment system using intermedium, and an exemplary treatment system is configured to output high-intensity focused ultrasound to remove bone tissue, inject an acoustically-transparent medium into a part where the bone tissue is removed to generate an intermedium, and output therapeutic ultrasound that passes through the intermedium. Accordingly, the bone tissue is removed in a non-invasive way using high-intensity focused ultrasound, and the intermedium is generated at the bone tissue removed site, to increase the penetration of therapeutic ultrasound or generate ultrasound itself, thereby improving an ultrasound treatment effect while minimizing the side effect (for example, infection of dura mater) of invasive surgery methods.

An ultrasound system performs cranial therapy using a headset mounted to the head of a subject which contains a therapy transducer and a motion detecting transducer. At the outset of therapy, echo signals are acquired by the motion detecting transducer and stored. Thereafter, echo signals are acquired again by the motion detecting transducer and compared or correlated with the signals stored at the outset of therapy. When a difference is determined between the compared or correlated signals, an alert is issued by the system that transducer motion or acoustic decoupling may have occurred.